

Understanding Recent Advances in IgAN

Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial

Rovin BH, Barratt J, Heerspink HJL, et al. Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial. *Lancet*. 2023;402(10417):2077-2090. doi:10.1016/S0140-6736(23)02302-4

<https://pubmed.ncbi.nlm.nih.gov/37931634/>

Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial

Heerspink HJL, Radhakrishnan J, Alpers CE, et al. Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial. *Lancet*. 2023;401(10388):1584-1594. doi:10.1016/S0140-6736(23)00569-X

<https://pubmed.ncbi.nlm.nih.gov/37015244/>

Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NeflgArd): 2-year results from a randomised phase 3 trial

Lafayette R, Kristensen J, Stone A, et al. Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NeflgArd): 2-year results from a randomised phase 3 trial [published correction appears in *Lancet*. 2023 Sep 9;402(10405):850]. *Lancet*. 2023;402(10405):859-870. doi:10.1016/S0140-6736(23)01554-4

<https://pubmed.ncbi.nlm.nih.gov/37591292/>

Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis

Rheault MN, Alpers CE, Barratt J, et al. Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis. *N Engl J Med*. Published online November 3, 2023.

doi:10.1056/NEJMoa2308550

<https://pubmed.ncbi.nlm.nih.gov/37921461/>

Povetacicept, an Enhanced Dual APRIL/BAFF Antagonist That Modulates B Lymphocytes and Pathogenic Autoantibodies for the Treatment of Lupus and Other B Cell-Related Autoimmune Diseases

Evans LS, Lewis KE, DeMonte D, et al. Povetacicept, an Enhanced Dual APRIL/BAFF Antagonist That Modulates B Lymphocytes and Pathogenic Autoantibodies for the Treatment of Lupus and Other B Cell-Related Autoimmune Diseases. *Arthritis Rheumatol*. 2023;75(7):1187-1202. doi:10.1002/art.42462

<https://pubmed.ncbi.nlm.nih.gov/36705554/>

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VIS649 (Sibeprenlimab), an APRIL-Neutralizing IgG₂ Monoclonal Antibody, in Healthy Volunteers

Mathur M, Barratt J, Suzuki Y, et al. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VIS649 (Sibeprenlimab), an APRIL-Neutralizing IgG₂ Monoclonal Antibody, in Healthy Volunteers. *Kidney Int Rep.* 2022;7(5):993-1003. Published 2022 Feb 8. doi:10.1016/j.ekir.2022.01.1073
<https://pubmed.ncbi.nlm.nih.gov/35570983/>